Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Fig. 1

DNA methylation profiles distinguish patients and healthy controls. a Principal component analysis shows a separation between patient and control samples after unsupervised analysis. We have analyzed a total of 25 bone marrow samples taken at diagnosis from patients with secondary acute myeloid leukemia (sAML) and 48 from patients with myelodysplastic syndrome (MDS). b Heatmap showing major methylation in neoplastic samples compared to healthy controls

Back to article page
\